Cancer Therapy and Research Center, Institution for Drug Development
San Antonio, Texas, 78229, United States
NCT Number: NCT00426140
The main purpose of this study is to characterize the distribution, metabolism, and elimination (ADME) of Patupilone after a single intravenous administration in patients with advanced solid tumor malignancies
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
San Antonio, Texas, 78229, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other protocol-defined inclusion/exclusion criteria may apply.
Time frame: one week
Time frame: every 6 weeks
Time frame: every 6 weeks
Novartis Pharmaceuticals
Industry
An Open-label Single Center Study to Characterize the Absorption, Distribution, Metabolism, and Elimination (ADME) of Patupilone (EPO906) After a Single Intravenous Administration of 10 mg/m2 [14C] Patupilone in Patients With Advanced Solid Tumor Malignancies.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00741403
Advanced Cancer, Advanced Malignancies
Peoria, Arizona, United States
View Trial DetailsNCT05059522
Adnexal Diseases, Advanced Malignancies
Fayetteville, Arkansas, United States
View Trial DetailsNCT04181788
Advanced Malignancies, Bronchial Neoplasms
Beijing, Beijing Municipality, China
View Trial DetailsNCT04164199
Advanced Malignancies
Miami, Florida, United States
View Trial Details